Biocartis Group NV

Declaration of Voting Results & Voting Rights Announcements • Jun 4, 2015

PRESS RELEASE (Regulated Information)

SHAREHOLDER NOTIFICATIONS

Mechelen, Belgium, June 5 th 2015 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company, announces today in accordance with article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provisions (the "Belgian Act") that it received shareholder notifications from several shareholders listed below.

Pursuant to the aforementioned notifications, the following shareholders hold the following number of shares and voting rights in the Company:

	Shares and voting rights held
	Number	% before exercise of the Over allotment Option(1) (2)	% after exercise of the Over allotment Option(1) (3)
Johnson & Johnson Innovation – JJDC, Inc.(4) 6,107,518		15.60	15.10
Debiopharm Diagnostics S.A.(5) 4,749,707		12.13	11.74
RMM S.A. (6) 3,989,058		10.19	9.86
Benaruca S.A. (7) 2,542,408		6.50	6.29
BIOSPV Limited (7) 539,834		1.38	1.33
Total of Benaruca S.A. and BIOSPV Limited (7)	3,082,242	7.87	7.62
PMV-TINA Comm.VA (8) 1,840,861		4.70	4.55
Participatie-Maatschappij Vlaanderen NV (8) 428,000		1.09	1.06
Total of PMV-TINA Comm.VA and Participatie
Maatschappij Vlaanderen NV (9) 2,268,861		5.80	5.61
Topbio1 LP (9) 1,804,644		4.61	4.46
Coöperatieve AESCAP Venture I U.A. (10) 1,440,850		3.68	3.56
Hitachi Chemical Co. Ltd (11) 1,417,346		3.62	3.50
Dham NV (12) 1,283,990		3.28	3.17

Notes:

_____________

⁽¹⁾ The "Over-allotment Option" relates to the option that was granted by the Company to KBC Securities NV, acting on behalf of the underwriters appointed by the Company in connection with its initial public offering (the "Offering"), to cover over-allotments in the Offering. The Over-allotment Option was exercised in full and as a result the Company issued 1,304,347 new shares on 19 May 2015.

⁽²⁾ Based on 39,144,013 outstanding shares before the exercise of the Over-allotment Option.

⁽³⁾ Based on 40,448,360 outstanding shares after the exercise of the Over-allotment Option.

• (4) Johnson & Johnson Innovation--JJDC, Inc., is a wholly owned subsidiary of Johnson & Johnson. Johnson & Johnson is not a controlled entity.
• (5) Debiopharm Diagnostics S.A. is controlled by Debiopharm Holding S.A., which is controlled by Rolland-Yves Mauvernay.
• (6) Rudi Mariën controls RMM S.A. RMM S.A. entered into a stock lending agreement with KBC Securities NV, as Global Coordinator with respect to the Offering, to allow KBC Securities NV to over-allot shares in the Offering within the framework of an over-allotment facility consisting of up to a maximum of 15% of the number of new shares that were effectively placed in the Offering (representing 1,304,347 shares). The 3,989,058 (amounting to 10.19%) of shares and voting rights before exercise of the Over-allotment Option include the number of voting rights attached to shares that were lent to KBC Securities NV in application of the stock lending agreement. On the date hereof, the stock lending agreement has ended and the shares that were lent to KBC Securities NV have been returned to RMM S.A.
• (7) Rudi Pauwels controls BioSPV Limited and Benaruca S.A.
• (8) Het Vlaams Gewest controls ParticipatieMaatschappij Vlaanderen nv. ParticipatieMaatschappij Vlaanderen nv owns 100% of the shares of PMV-TINA Comm.VA and hence controls PMV-TINA Comm.VA.
• (9) Topbio 1 LP is not a controlled entity.
• (10) Aescap Venture I Management BV controls Cooperatieve Aescap Venture I U.A. Aescap Venture I Management BV is not a controlled entity.
• (11) 51.2% shares of Hitachi Chemical Co., Ltd. is directly held by Hitachi, Ltd., which is a parent company of Hitachi Chemical Co., Ltd. Hitachi Ltd is not a controlled entity.
• (12) DHAM NV is controlled by Halse Investeringsmaatschappij NV, which is controlled by Korys NV, which in turn is controlled by Stichting Administratiekantoor Cozin. Stak Cozin is not a controlled entity.

Copies of the aforementioned notifications are available on the Company's website.

Pursuant to the Belgian Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

Biocartis

Rudi Pauwels, CEO/Hilde Windels, CFO +32 15 632 600 press@biocartis.com

Consilium Strategic Communications

Amber Bielecka/Jessica Hodgson/Chris Welsh/Laura Thornton +44 (0) 203 709 5701 (London, UK) biocartis@consilium-comms.com

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company's proprietary MDx Idylla™ platform is a fully automated, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF mutations in metastatic melanoma. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide.

Further information can be found at: www.biocartis.com